For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) compared to a net loss of €162.2 million, or €2.88 per share (basic and ...
Q3 Revenue Amid Cost Reductions: While successfully reducing expenses, Revenue was $593 thousand during the quarter ended September 30, 2024, bringing year-to-date revenue to $3.6 million for the nine ...
Revenue for the third quarter of 2024 was $1,885,322 which represents an 8.9% quarter over quarter increase. Product sales of $1,328,675 made up the bulk of the revenue with the remainder coming from ...